Effect of SLCO1B1 genotypes on statin intolerance and response to statins

Abstract Background Statins are a cornerstone therapy for management of hypercholesterolaemia in primary and secondary prevention cardiovascular disease, however there is individual variation regarding efficacy adverse side-effects experienced. Purpose Polymorphisms the SLCO1B1 gene have shown correlation with risk statin treatment, real-world clinical practice, their utility remains to be established. Methods We carried out retrospective multiple linear regression analysis using robust standard errors 129 individuals undergoing genetic testing polymorphisms rs4149056 rs2306283 investigate an association side effects respectively. In addition, logistic regressions which account binary nature outcomes were performed. The has 3 outcomes: T/T (considered least associated intolerance), C/C most intolerance) T/C intermediately intolerance). A/A response), G/G response) A/G response). Results According analyses genotypes (C/C relative base type T/T) do not predict incidence myalgia, myopathy, creatine kinase rise, liver function derangement or gastrointestinal at 5% significance. (G/G A/A) LDL response statins (p-values 0.33 0.52 respectively). Conclusions presence was increased side-effects. Similarly did correlate treatment. These genotype predictors primarily based on Simvastatin – earlier generation statin, whereas majority patients this cohort treated more contemporary widely used such as Atorvastatin Rosuvastatin. therefore conclude that these genotypic markers may limited application modern day practice substantial investment resources towards them justified. Funding Acknowledgement Type funding sources: None.